BIOXODES
ActiveSummary
BIOXODES has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-1.66M) and a net result of €-3.44M. Equity is shrinking by ~11.1% per year across the filed fiscal years. Its solvency ranks better than 9% of 191 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability0=
Solvency3▼-62
Growth32▼-20
Track record100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.35 against 2.0 in 2024; short-term debt: 81.4% and cash: 26.5% of total assets), and equity is negative.
Credit check for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-21.6%
Return on assets
-44.8%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €-1.66M
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
29 d early
2024
15 d early
2023
8 d early
2022
17 d early
2021
23 d late
2020
18 d early
2019
4 d late
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€-3.44M▲ 14.4%
2024 · €-4.02M
2018: €-1.26Mhighest in 8 years
2019: €-1.30M▼ -2.9% vs 2018
2020: €-2.00M▼ -53.7% vs 2019
2021: €-2.17M▼ -8.4% vs 2020
2022: €-2.00M▲ +7.6% vs 2021
2023: €-4.88M▼ -143% vs 2022lowest in 8 years
2024: €-4.02M▲ +17.6% vs 2023
2025: €-3.44M▲ +14.4% vs 2024
2018 → 2025
Working capital
€-4.06M
2024 · €1.09M
2018: €1.15M
2019: €4.32M▲ +276% vs 2018
2020: €2.11M▼ -51.1% vs 2019
2021: €5.77M▲ +173% vs 2020highest in 8 years
2022: €2.90M▼ -49.8% vs 2021
2023: €4.00M▲ +38.1% vs 2022
2024: €1.09M▼ -72.8% vs 2023
2025: €-4.06M▼ -473% vs 2024lowest in 8 years
2018 → 2025
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€9.21M-€6.72M▼ 27.0%€6.92M▲ 3.0%€2.81M▼ 59.4%€-1.66M
2021: €9.21Mhighest in 5 years
2022: €6.72M▼ -27.0% vs 2021
2023: €6.92M▲ +3.0% vs 2022
2024: €2.81M▼ -59.4% vs 2023
2025: €-1.66M▼ -159% vs 2024lowest in 5 years
Operating result€-2.16M-€-1.99M▲ 8.3%€-4.87M▼ 145%€-4.01M▲ 17.6%€-3.18M▲ 20.7%
2021: €-2.16M
2022: €-1.99M▲ +8.3% vs 2021highest in 5 years
2023: €-4.87M▼ -145% vs 2022lowest in 5 years
2024: €-4.01M▲ +17.6% vs 2023
2025: €-3.18M▲ +20.7% vs 2024
Net result€-2.17M-€-2.00M▲ 7.6%€-4.88M▼ 143%€-4.02M▲ 17.6%€-3.44M▲ 14.4%
2021: €-2.17M
2022: €-2.00M▲ +7.6% vs 2021highest in 5 years
2023: €-4.88M▼ -143% vs 2022lowest in 5 years
2024: €-4.02M▲ +17.6% vs 2023
2025: €-3.44M▲ +14.4% vs 2024
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €3.18M in 2025 against €4.01M in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €7.68M
Fixed assets
€5.49M ▲ 14.0%
Current assets
€2.20M ▲ 0.7%
Key figures and ratios
EBITDA
€-1.26M▲
2024 · €-1.88M
Cash flow
€-1.52M▲
2024 · €-1.88M
Solvency
-21.6%▼
2024 · 40.2%
Current ratio
0.35▼
2024 · 2.00
Debt to equity
-5.62▼
2024 · 1.49
ROA
-44.8%▲
2024 · -57.5%
Interest coverage
-4.83▲
2024 · -334.87
Debt
€9.34M▲
2024 · €4.18M
Debt ≤ 1 year
€6.25M▲
2024 · €1.09M
Debt > 1 year
€3.07M=
2024 · €3.07M
Income taxes
€1k▼
2024 · €1k
Staff costs
€1.14M▲
2024 · €987k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 55 lines
Balance sheet
Code20242025
Assets
Total assets20/58€6.99M€7.68M▲
Fixed assets21/28€4.81M€5.49M▲
Intangible fixed assets21€4.80M€5.47M▲
Tangible fixed assets22/27€11k€10k▼
Plant, machinery and equipment23€0-
Furniture and vehicles24€9k€9k▼
Other tangible fixed assets26€2k€2k▼
Financial fixed assets28€174€174=
Current assets29/58€2.18M€2.20M▲
Amounts receivable within one year40/41€850k€139k▼
Trade receivables40€2k€9k▲
Other amounts receivable41€848k€130k▼
Cash at bank and in hand54/58€1.32M€2.04M▲
Deferred charges and accrued income490/1€13k€21k▲
Equity and liabilities
Total equity and liabilities10/49€6.99M€7.68M▲
Equity10/15€2.81M€-1.66M▼
Contributions10/11€9.47M€396k▼
Capital10€1.07M€396k▼
Issued capital100€1.07M€396k▼
Outside capital11€8.40M€0▼
Share premium1100/10€8.40M€0▼
Profit (loss) carried forward14€-9.07M€-3.44M▲
Investment grants15€2.41M€1.38M▼
Amounts payable17/49€4.18M€9.34M▲
Amounts payable after more than one year17€3.07M€3.07M=
Other amounts payable178/9€3.07M€3.07M=
Amounts payable within one year42/48€1.09M€6.25M▲
Financial debts43-€5.75M
Other loans439-€5.75M
Trade debts44€539k€400k▼
Suppliers440/4€539k€400k▼
Taxes, remuneration and social security45€181k€104k▼
Taxes450/3€30k€3k▼
Remuneration and social security454/9€151k€101k▼
Other amounts payable47/48€372k€0▼
Accrued charges and deferred income492/3€25k€23k▼
Income statement
Code20242025
Non-recurring operating income76A-€270
Remuneration, social security and pensions62€987k€1.14M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2.14M€1.92M▼
Other operating charges640/8€1k€5k▲
Non-recurring operating charges66A€629€0▼
Gross operating margin9900€-889k€-112k▲
Operating profit (loss)9901€-4.01M€-3.18M▲
Financial income75/76B€2k€6k▲
Recurring financial income75€2k€6k▲
Financial charges65/66B€6k€262k▲
Recurring financial charges65€6k€262k▲
Profit (loss) for the period before taxes9903€-4.02M€-3.44M▲
Income taxes67/77€1k€1k▼
Profit (loss) for the period9904€-4.02M€-3.44M▲
Profit (loss) for the period to be appropriated9905€-4.02M€-3.44M▲
Appropriation of the result
Profit (loss) to be appropriated9906€-9.07M€-12.51M▼
Profit (loss) brought forward from the previous period14P€-5.05M€-9.07M▼
Transfer from equity791/2-€9.07M
Social balance
Average headcount (FTE)90878.87.7▼
The notes to these accounts (26 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Accounts by statement
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | €270 | - |
| Remuneration, social security and pensions62 | €584k | €1.01M | €1.07M | €987k | €1.14M | ▲ 16.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €2.34M | €1.95M | €2.11M | €2.14M | €1.92M | ▼ 10.1% |
| Other operating charges640/8 | €858 | €4k | €5k | €1k | €5k | ▲ 371% |
| Non-recurring operating charges66A | - | - | - | €629 | €0 | ▼ 100% |
| Gross operating margin9900 | €758k | €973k | €-1.69M | €-889k | €-112k | ▲ 87.3% |
| Operating profit (loss)9901 | €-2.16M | €-1.99M | €-4.87M | €-4.01M | €-3.18M | ▲ 20.7% |
| Financial income75/76B | €0 | €45 | €218 | €2k | €6k | ▲ 176% |
| Recurring financial income75 | €0 | €45 | €218 | €2k | €6k | ▲ 176% |
| Financial charges65/66B | €3k | €18k | €4k | €6k | €262k | ▲ 4,566% |
| Recurring financial charges65 | €3k | €18k | €4k | €6k | €262k | ▲ 4,566% |
| Profit (loss) for the period before taxes9903 | €-2.17M | €-2.00M | €-4.87M | €-4.02M | €-3.44M | ▲ 14.4% |
| Income taxes67/77 | €413 | €875 | €1k | €1k | €1k | ▼ 2.1% |
| Profit (loss) for the period9904 | €-2.17M | €-2.00M | €-4.88M | €-4.02M | €-3.44M | ▲ 14.4% |
| Profit (loss) for the period to be appropriated9905 | €-2.17M | €-2.00M | €-4.88M | €-4.02M | €-3.44M | ▲ 14.4% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €11.37M | €8.96M | €10.26M | €6.99M | €7.68M | ▲ 9.9% |
| Fixed assets21/28 | €5.04M | €5.17M | €4.83M | €4.81M | €5.49M | ▲ 14.0% |
| Intangible fixed assets21 | €5.02M | €5.15M | €4.81M | €4.80M | €5.47M | ▲ 14.1% |
| Tangible fixed assets22/27 | €21k | €20k | €15k | €11k | €10k | ▼ 3.7% |
| Plant, machinery and equipment23 | €3k | €2k | €699 | €0 | - | - |
| Furniture and vehicles24 | €17k | €17k | €12k | €9k | €9k | ▼ 0.7% |
| Other tangible fixed assets26 | €2k | €1k | €2k | €2k | €2k | ▼ 17.5% |
| Financial fixed assets28 | €174 | €174 | €174 | €174 | €174 | = |
| Current assets29/58 | €6.33M | €3.79M | €5.43M | €2.18M | €2.20M | ▲ 0.7% |
| Amounts receivable within one year40/41 | €103k | €127k | €453k | €850k | €139k | ▼ 83.6% |
| Trade receivables40 | €196 | €0 | €306k | €2k | €9k | ▲ 476% |
| Other amounts receivable41 | €103k | €127k | €147k | €848k | €130k | ▼ 84.6% |
| Cash at bank and in hand54/58 | €6.22M | €3.66M | €4.97M | €1.32M | €2.04M | ▲ 54.5% |
| Deferred charges and accrued income490/1 | €8k | €7k | €9k | €13k | €21k | ▲ 66.0% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €11.37M | €8.96M | €10.26M | €6.99M | €7.68M | ▲ 9.9% |
| Equity10/15 | €9.21M | €6.72M | €6.92M | €2.81M | €-1.66M | ▼ 159% |
| Contributions10/11 | €14.26M | €5.69M | €9.42M | €9.47M | €396k | ▼ 95.8% |
| Capital10 | €691k | €691k | €1.06M | €1.07M | €396k | ▼ 62.9% |
| Issued capital100 | €691k | €691k | €1.06M | €1.07M | €396k | ▼ 62.9% |
| Outside capital11 | €13.56M | €5.00M | €8.36M | €8.40M | €0 | ▼ 100% |
| Share premium1100/10 | €13.56M | €5.00M | €8.36M | €8.40M | €0 | ▼ 100% |
| Profit (loss) carried forward14 | €-6.73M | €-175k | €-5.05M | €-9.07M | €-3.44M | ▲ 62.1% |
| Investment grants15 | €1.69M | €1.20M | €2.55M | €2.41M | €1.38M | ▼ 42.7% |
| Amounts payable17/49 | €2.17M | €2.25M | €3.34M | €4.18M | €9.34M | ▲ 123% |
| Amounts payable after more than one year17 | €1.55M | €1.32M | €1.88M | €3.07M | €3.07M | = |
| Other amounts payable178/9 | €1.55M | €1.32M | €1.88M | €3.07M | €3.07M | = |
| Amounts payable within one year42/48 | €559k | €892k | €1.43M | €1.09M | €6.25M | ▲ 473% |
| Current portion of amounts payable after more than one year42 | €400k | €636k | €872k | - | - | - |
| Financial debts43 | - | - | - | - | €5.75M | - |
| Other loans439 | - | - | - | - | €5.75M | - |
| Trade debts44 | €90k | €140k | €400k | €539k | €400k | ▼ 25.7% |
| Suppliers440/4 | €90k | €140k | €400k | €539k | €400k | ▼ 25.7% |
| Taxes, remuneration and social security45 | €69k | €116k | €155k | €181k | €104k | ▼ 42.7% |
| Taxes450/3 | €686 | €1k | €7k | €30k | €3k | ▼ 89.9% |
| Remuneration and social security454/9 | €68k | €115k | €149k | €151k | €101k | ▼ 33.4% |
| Other amounts payable47/48 | - | - | - | €372k | €0 | ▼ 100% |
| Accrued charges and deferred income492/3 | €53k | €33k | €29k | €25k | €23k | ▼ 8.9% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €-2.17M | €-2.00M | €-4.88M | €-4.02M | €-3.44M | ▲ 14.4% |
| + Depreciation and write-downs630 | €2.34M | €1.95M | €2.11M | €2.14M | €1.92M | ▼ 10.1% |
| Operating cash flow (approximation) | €169k | €-57k | €-2.77M | €-1.88M | €-1.52M | ▲ 19.2% |
| Investment in fixed assets (approximation) | - | €-2.08M | €-1.76M | €-2.12M | €-2.60M | ▼ 22.5% |
| Change in cash | - | €-2.57M | €1.31M | €-3.65M | €719k | ▲ 120% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
07-08
State Gazette act
Reappointments: SRL XMF, SRL PHMBIO+ and 3 othersPermanent representatives: Marc DECHAMPS, Philippe MONTEYNE and 4 others · Appointments: SRL XMF, SRL PHMBIO+ and SRL PwC Réviseurs d'Enreprises16 facts ▸
State Gazette act
Reappointments: SRL XMF, SRL PHMBIO+ and 3 others
Permanent representatives: Marc DECHAMPS, Philippe MONTEYNE and 4 others · Appointments: SRL XMF, SRL PHMBIO+ and SRL PwC Réviseurs d'Enreprises16 facts ▸
- General meeting, 30/06/2026
- Director reappointment, SRL XMF (director)
- Director reappointment, SRL PHMBIO+ (director)
- Director reappointment, SC CAPITAL & CROISSANCE (director)
- Director reappointment, SA S.F.P.I. (Société Fédérale de Participations et d'Investissements) (director)
- Director reappointment, SAS CROUGHS R&D CONSULTING (director)
- Permanent representative, Marc DECHAMPS
- Permanent representative, Philippe MONTEYNE
- Permanent representative, Pierre DETRIXHE
- Permanent representative, François FONTAINE
- Permanent representative, Thérèse CROUGHS
- Board meeting, 03/07/2026
- +4 further facts in this act
02-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
16-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
23-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Weakest financial yearnet €-4.88M
Net result drops to €-4.88M, the lowest in the series; recovery starts the following year.
14-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
23-08
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 23 days late
2021
13-07
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
04-08
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 4 days late
2019
31-12
Financial
Equity above €5MEq €7.91M ▲284%
Equity rises from €2.06M to €7.91M.
25-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
31-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
08-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 8 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 32 acts read
About the unread acts
Of the 32 Belgian State Gazette acts we know for this company, 1 has been read. The other 31 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
under verification, last change in 2026
This board is reconstructed from a single act (26101729). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
CAPITAL & CROISSANCE
CurrentDirector · since 01-07-2026 · Cooperative company · perm. rep.: Pierre DETRIXHE
PHMBIO+
CurrentDirector · since 01-07-2026 · Private limited company · perm. rep.: Philippe MONTEYNE
SAS CROUGHS R&D CONSULTING
CurrentDirector · since 01-07-2026 · Legal entity · perm. rep.: Thérèse CROUGHS
SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT
CurrentDirector · since 01-07-2026 · Public limited company · perm. rep.: François FONTAINE
XMF
CurrentDirector · since 01-07-2026 · Private limited company · perm. rep.: Marc DECHAMPS
01-07-2026
CAPITAL & CROISSANCE: Mandate renewed as Director
01-07-2026
PHMBIO+: Mandate renewed as Director
01-07-2026
PHMBIO+: Appointed as Présidence du conseil d'administration
01-07-2026
SAS CROUGHS R&D CONSULTING: Mandate renewed as Director
01-07-2026
SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT: Mandate renewed as Director
Not every act has been read: a resignation may be missing here
31 of this company's 32 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Charleroi · 1 establishment unit since 2010
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue Santos - Dumont 16041 Charleroi1 establishment unit
BIOXODES
since 20102.187.055.535
Statutory auditor
1 auditor| SRL PwC Réviseurs d'EnreprisesCurrent Statutory auditor · represented by Didier DELANOYE | 07-08-2026 → present |
Structure & network
Connections & network
32 connected companiesThis company
Company
Director
Shareholding
Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Show 28 more companies with a shared director
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Similar companies · same sector, comparable size
Dr. J. Bellon
BE 0456.618.392
Buggenhout · Eq €2.85M
Dr. Lieven WOSTYN
BE 0467.516.640
Koksijde · Eq €2.70M
EXO Biologics
BE 0732.982.379
Liège · Eq €2.93M
Montis Biosciences
BE 0730.979.429
Leuven · Eq €2.95M
K5 Therapeutics
BE 0757.718.072
Leuven · Eq €2.96M
Of 762 companies in sector 72101 we hold annual accounts for 481. 240 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded20-04-2010
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
Scores and ratios are computed by Checked and are not a credit decision.